MGC Pharmaceuticals appoints Mr. Layton Mills as a Non-Executive Director

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced the appointment of Mr. Layton Mills as a Non-Executive Director of the Company effective immediately.

Mr. Mills is an experienced life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing significant experience across human and animal health in pharmaceutical and consumer healthcare.

Mr. Mills is the founder of CannPal Animal Therapeutics Pty Ltd, an Animal Health Company developing cannabinoid-based veterinary medicines for FDA-CVM registration, which he led through an Initial Public Offering on the Australian Stock Exchange, followed by an acquisition by AusCann Group Holdings in 2021 where he served as CEO. Mr Mills is also the founder and Managing Director of Subgenix Lifesciences, an early-stage biotechnology Company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs.

He has extensive international business experience having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.

MGC Pharmaceuticals is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    MGC Pharmaceuticals

    More articles like this

    MGC Pharmaceuticals

    MGC Pharmaceuticals secures US$7.9 million in new fund raising

    MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured

    MGC Pharmaceuticals

    MGC Pharmaceuticals positive clinical trial results for CimetrA

    MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral

    MGC Pharmaceuticals

    MGC Pharmaceuticals reports on a very productive June quarter

    MGC Pharmaceuticals Ltd (LON:MXC), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has provided its Quarterly Activity Report for the three months ending 30th June 2023. Key Highlights: ·      CannEpil®, MGC

    MGC Pharmaceuticals

    MGC Pharmaceuticals CannEpil received by first patients in the UK

    MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced that CannEpil®, MGC Pharma’s IMP has now been successfully imported and received by its first patients in